ES2654674T3 - Método para seleccionar compuestos usando membrana de STIM1 - Google Patents

Método para seleccionar compuestos usando membrana de STIM1 Download PDF

Info

Publication number
ES2654674T3
ES2654674T3 ES14290232.9T ES14290232T ES2654674T3 ES 2654674 T3 ES2654674 T3 ES 2654674T3 ES 14290232 T ES14290232 T ES 14290232T ES 2654674 T3 ES2654674 T3 ES 2654674T3
Authority
ES
Spain
Prior art keywords
cells
stim1
antibody
protein
plasma membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14290232.9T
Other languages
English (en)
Spanish (es)
Inventor
Yves Renaudineau
Olivier Mignen
Miguel Burgos
Jacques Olivier Pers
Tinhinane Fali
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Hospitalier Regional et Universitaire de Brest
Univerdite de Bretagne Occidentale
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Hospitalier Regional et Universitaire de Brest
Univerdite de Bretagne Occidentale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Centre Hospitalier Regional et Universitaire de Brest, Univerdite de Bretagne Occidentale filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Application granted granted Critical
Publication of ES2654674T3 publication Critical patent/ES2654674T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G01N33/57505—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES14290232.9T 2014-08-06 2014-08-06 Método para seleccionar compuestos usando membrana de STIM1 Active ES2654674T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14290232.9A EP2982982B1 (en) 2014-08-06 2014-08-06 Method of screening of compounds using membrane STIM1

Publications (1)

Publication Number Publication Date
ES2654674T3 true ES2654674T3 (es) 2018-02-14

Family

ID=51398585

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14290232.9T Active ES2654674T3 (es) 2014-08-06 2014-08-06 Método para seleccionar compuestos usando membrana de STIM1

Country Status (11)

Country Link
US (2) US20170219588A1 (enExample)
EP (2) EP2982982B1 (enExample)
JP (2) JP6754751B2 (enExample)
CN (2) CN110051836B (enExample)
CA (1) CA2952159C (enExample)
DK (1) DK2982982T3 (enExample)
ES (1) ES2654674T3 (enExample)
NO (1) NO2982982T3 (enExample)
PL (1) PL2982982T3 (enExample)
PT (1) PT2982982T (enExample)
WO (1) WO2016020274A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3714943A1 (en) 2019-03-25 2020-09-30 Université De Bretagne Occidentale - UBO Monoclonal antibody against stim1
EP3715848A1 (en) * 2019-03-25 2020-09-30 Université de Bretagne Occidentale (U.B.O.) Substance interacting with c terminal fragment of the stim1 fraction localized to the plasma membrane of the cells, for its use in the treatment of cancers, and in screening and diagnostic methods
EP3714942A1 (en) * 2019-03-25 2020-09-30 Université De Bretagne Occidentale - UBO Monoclonal antibody against stim1
US20240083990A1 (en) * 2021-01-26 2024-03-14 Universite Brest Bretagne Occidentale Novel stim1 splicing variants and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2341484T3 (es) * 2005-05-20 2010-06-21 Genentech, Inc. Pretratamiento de una muestra biologica de un sujeto que sufre una enfermedad autoinmune.
WO2008148108A1 (en) * 2007-05-24 2008-12-04 Calcimedica, Inc. Calcium channel proteins and uses thereof
US20160169868A9 (en) * 2007-05-24 2016-06-16 Calcimedica, Inc. Calcium channel proteins and uses thereof
EP2472262A3 (en) * 2007-07-10 2012-10-17 Immune Disease Institute, Inc. Stromal interacting molecule knockout mouse and uses thereof
WO2009021338A1 (en) * 2007-08-15 2009-02-19 UNIVERSITé DE SHERBROOKE Alternative splicing gene variants in cancer detection
AU2008299220B2 (en) * 2007-09-10 2011-07-21 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2103311A1 (en) * 2008-03-20 2009-09-23 CSL Behring GmbH The calcium sensor STIM1 is essential for pathological thrombus formation
WO2010099401A1 (en) * 2009-02-26 2010-09-02 The Board Of Trustees Of The Leland Stanford Junior University Calcium signaling modulators involving stim and orai proteins
US8993612B2 (en) * 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
US20160194393A1 (en) * 2011-08-10 2016-07-07 Biommune Technologies Inc. Methods and compositions for modulating voltage-gated calcium channel function
CN102433383B (zh) * 2011-12-19 2015-07-08 上海吉凯基因化学技术有限公司 人stim1基因的用途及其相关药物

Also Published As

Publication number Publication date
NO2982982T3 (enExample) 2018-03-03
PT2982982T (pt) 2018-01-03
JP2019214576A (ja) 2019-12-19
JP6861246B2 (ja) 2021-04-21
CA2952159A1 (en) 2016-02-11
PL2982982T3 (pl) 2018-03-30
EP3177929A1 (en) 2017-06-14
US20170219588A1 (en) 2017-08-03
JP6754751B2 (ja) 2020-09-16
JP2017531164A (ja) 2017-10-19
EP2982982B1 (en) 2017-10-04
CN110051836A (zh) 2019-07-26
CN106716130B (zh) 2019-03-29
EP2982982A1 (en) 2016-02-10
US20190154690A1 (en) 2019-05-23
CA2952159C (en) 2022-08-30
DK2982982T3 (en) 2018-01-08
WO2016020274A1 (en) 2016-02-11
CN110051836B (zh) 2023-05-26
EP3177929B1 (en) 2018-05-09
CN106716130A (zh) 2017-05-24

Similar Documents

Publication Publication Date Title
Croce et al. Targeted therapy of uveal melanoma: Recent failures and new perspectives
Wen et al. N-myristoyltransferase deficiency impairs activation of kinase AMPK and promotes synovial tissue inflammation
Zhang et al. Aldehyde dehydrogenase 2 mediates alcohol‐induced colorectal cancer immune escape through stabilizing PD‐L1 expression
Fuhlbrigge et al. CD43 is a ligand for E-selectin on CLA+ human T cells
Noonan et al. A novel role of IL-17–producing lymphocytes in mediating lytic bone disease in multiple myeloma
Ittner et al. Regulation of PTEN activity by p38δ-PKD1 signaling in neutrophils confers inflammatory responses in the lung
Yu et al. Metabolic control of regulatory T cell stability and function by TRAF3IP3 at the lysosome
Mensah et al. CD24 expression and B cell maturation shows a novel link with energy metabolism: potential implications for patients with myalgic encephalomyelitis/chronic fatigue syndrome
Rupertus et al. Interaction of the chemokines I-TAC (CXCL11) and SDF-1 (CXCL12) in the regulation of tumor angiogenesis of colorectal cancer
Qian et al. Adiponectin aggravates bone erosion by promoting osteopontin production in synovial tissue of rheumatoid arthritis
Muthusamy et al. ShcA protects against epithelial–mesenchymal transition through compartmentalized inhibition of TGF-β-induced Smad activation
Miao et al. NSun2 regulates aneurysm formation by promoting autotaxin expression and T cell recruitment
Till et al. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells
Xuan et al. Targeting CD276 by CAR-T cells induces regression of esophagus squamous cell carcinoma in xenograft mouse models
ES2654674T3 (es) Método para seleccionar compuestos usando membrana de STIM1
Estupinan et al. Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effects
Deng et al. Tumor cell cross talk with tumor-associated leukocytes leads to induction of tumor exosomal fibronectin and promotes tumor progression
Lee et al. Intracellular Adhesion Molecule‐1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8+ T Cells
Schmid et al. PI3Kγ stimulates a high molecular weight form of myosin light chain kinase to promote myeloid cell adhesion and tumor inflammation
Marrone et al. Alternative splicing of FKBP5 gene exerts control over T lymphocyte expansion
Mester et al. CD40 expression in fibrocytes is induced by TSH: potential synergistic immune activation
Dobson et al. Targeting cancer stem cells via integrin β4
Jiang et al. Myeloperoxidase-anchored ENO1 mediates neutrophil extracellular trap DNA to enhance Treg differentiation via IFITM2 during sepsis
Zhang et al. The pleckstrin homology domain adaptor protein Bam32/DAPP1 is required for germinal center progression
Ao et al. Targeting GFPT2 to reinvigorate immunotherapy in EGFR-mutated NSCLC